A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms SECU_Trial
- 08 Oct 2019 Planned End Date changed from 1 Jul 2020 to 1 Mar 2021.
- 08 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 May 2020.
- 19 Oct 2018 Status changed from not yet recruiting to recruiting.